Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, 12-Week, Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate Efficacy and Safety of GX-G6 on Glycaemic Control Versus Placebo and Open-Label Dulaglutide in Patients With Uncontrolled Type 2 Diabetes Mellitus

NCT03962010 is registered in ClinicalTrials.gov with Genexine, Inc. as lead sponsor.

NCT NCT03962010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03962010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, 12-Week, Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate Efficacy and Safety of GX-G6 on Glycaemic Control Versus Placebo and Open-Label Dulaglutide in Patients With Uncontrolled Type 2 Diabetes Mellitus
Lead sponsor
Genexine, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2019
Completion date
July 1, 2022
Enrollment
78 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus